The Rs 1,350-crore IPO of Alkem Lab was oversubscribed 33.08 times, receiving bids for 30,06,38,100 shares against the total issue size of 90,87,084 shares, data available with the NSE till 1500 hrs showed.
Similarly, the Rs 638-crore IPO of Dr Lal PathLabs received bids for 16,84,66,960 shares as against the total issue size of 81,20,000 shares, generating an oversubscription of 20.75 times.
Together will raise about Rs 2,000 crore from the public.
Both the public issues managed to get oversubscribed on the second day of the three-day issue.
Also Read
Alkem Laboratories has raised Rs 395 crore from anchor investors, including Abu Dhabi Investment Fund, by allotting shares at a price of Rs 1,050.
For the IPO, the company has fixed a price band of Rs 1,020-1,050. Through the initial share sale, which closes today, Alkem aims to raise up to Rs 1,350 crore.
The global coordinators and book running lead managers (GCBRLMs) to the issue are Nomura Financial Advisory and Securities (India), Axis Capital Ltd, JP Morgan India Pvt Ltd and Edelweiss Financial Services Ltd.
Meanwhile, Dr Lal PathLabs has raised over Rs 191 crore from anchor investors by selling shares at a price of Rs 550 apiece.
The company's IPO, which aims to raise up to Rs 638 crore, would close today. Price band for the offer has been fixed at Rs 540-550 per share.
Kotak Mahindra Capital Company and Citigroup Global Markets India Private are the book running lead managers to the issue.
This year, 18 companies have so far launched IPOs, raising more than Rs 12,000 crore, making it the best in four years in terms of fund raising through initial share-sale programmes.